Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer

To assess the role of germline pathogenic variants (PVs) in SMARCA4 and further established ovarian cancer (OC) predisposition genes in early onset OC, we investigated a clinical cohort of 206 unrelated OC index patients with an age at diagnosis of OC ≤40 years using an extended panel of 24 (candidate) cancer predisposition genes. PVs in established OC predisposition genes were most frequent in patients with high grade serous OC (21/62, 33.9%), comparatively rare in patients with epithelial OC other than high grade serous (5/74, 6.8%) or borderline ovarian tumours (2/39, 5.1%) and absent in mucinous OC (0/27). We demonstrate that germline PVs in SMARCA4 unlikely predispose for early onset OC other than SCCOHT.

[1]  R. Schmutzler,et al.  HerediCaRe: Dokumentations- und IT-Lösung eines spezialisierten Registers für erblichen Brust- und Eierstockkrebs , 2021, Das Gesundheitswesen.

[2]  R. Schmutzler,et al.  Performance of In Silico Prediction Tools for the Detection of Germline Copy Number Variations in Cancer Predisposition Genes in 4208 Female Index Patients with Familial Breast and Ovarian Cancer , 2021, Cancers.

[3]  J. Trent,et al.  Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines , 2020, Clinical Cancer Research.

[4]  Julie O. Culver,et al.  Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D , 2020, Journal of the National Cancer Institute.

[5]  E. Kohn,et al.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Julie O. Culver,et al.  Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Aung Ko Win,et al.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[8]  A. Leary,et al.  Mucinous Ovarian Carcinoma. , 2019, The New England journal of medicine.

[9]  F. Couch,et al.  Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. , 2017, Gynecologic oncology.

[10]  A. Reuss,et al.  Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) , 2017, PloS one.

[11]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[12]  J. Trent,et al.  The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. , 2016, Gynecologic oncology.

[13]  T. Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[14]  P. Ewing-Graham,et al.  Clinical Management of Ovarian Small-Cell Carcinoma of the Hypercalcemic Type: A Proposal for Conservative Surgery in an Advanced Stage of Disease , 2009, International Journal of Gynecologic Cancer.

[15]  E. Oliva,et al.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Clinicopathological Analysis of 150 Cases , 1994, The American journal of surgical pathology.

[16]  M. Munsell,et al.  Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases. , 2016, Gynecologic oncology.